Clinical research

DOI: 10.4244/EIJ-D-23-00361

Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation: one-year results of the DRAGONFLY-DMR trial

Jian'an Wang1, MD, PhD; Xianbao Liu1, MD, PhD; Zhaoxia Pu1, MD; Mao Chen2, MD, PhD; Zhenfei Fang3, MD, PhD; Jun Jin4, MD; Jianzhen Dong5, MD, PhD; Yansong Guo6, MD, PhD; Biao Cheng7, MD; Jiancheng Xiu8, MD, PhD; Jianfang Luo9, MD; Yida Tang10, MD, PhD; Yan Wang11, MD, PhD; Xiaomen Chen12, MD, PhD; Gejun Zhang13, MD, PhD; Yibing Shao14, MD, PhD; Guangyuan Song15, MD, PhD; Lang Hong16, MD; Hong Jiang17, MD, PhD; Yangqin Wu18, MD, PhD; Yiqiang Yuan19, MD; Lianglong Chen20, MD, PhD; Ben He21, MD, PhD; Jingfeng Wang22, MD, PhD; Kai Xu23, MD; Yining Yang24, MD, PhD; Daxin Zhou25, MD, PhD; Qi Zhang26, MD, PhD; Yi Li27, MD; Kangmu Ma28, MD, PhD; Yat-Yin Lam29, MD; Yaling Han23, MD, PhD; Junbo Ge25, MD, PhD; D. Scott Lim30, MD; for the DRAGONFLYDMR Pivotal Trial Investigators

Abstract

BACKGROUND: Severe degenerative mitral regurgitation (DMR) can cause a poor prognosis if left untreated. For patients considered at prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) has become an accepted alternative therapy. The DragonFly transcatheter valve repair system is an innovative evolution of the mitral TEER device family to treat DMR.

AIMS: Herein we report on the DRAGONFLY-DMR trial (ClinicalTrials.gov: NCT04734756), which was a prospective, single-arm, multicentre study on the safety and effectiveness of the DragonFly system.

METHODS: A total of 120 eligible patients with prohibitive surgical risk and DMR ≥3+ were screened by a central eligibility committee for enrolment. The study utilised an independent echocardiography core laboratory and clinical event committee. The primary endpoint was the clinical success rate, which measured freedom from all-cause mortality, mitral valve reintervention, and mitral regurgitation (MR) >2+ at 1-year follow-up.

RESULTS: At 1 year, the trial successfully achieved its prespecified primary efficacy endpoint, with a clinical success rate of 87.5% (95% confidence interval: 80.1-92.3%). The rates of major adverse events, all-cause mortality, mitral valve reintervention, and heart failure hospitalisation were 9.0%, 5.0%, 0.8%,...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 4
Feb 19, 2024
Volume 20 Number 4
View full issue


Key metrics

On the same subject

Image – Interventional flashlight

10.4244/EIJ-D-23-00302 Dec 18, 2023
First-in-human experience with a novel transcatheter direct annuloplasty system for severe atrial functional mitral regurgitation
Zhu Z et al

EXPERT REVIEW

10.4244/EIJ-D-18-00511 Sep 7, 2018
Transcatheter mitral valve repair: review of the clinical evidence
Taramasso M et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00673 Sep 24, 2017
Transcatheter mitral valve replacement: device landscape and early results
Patel A and Bapat VN
free

10.4244/EIJV13I3A37 Jun 20, 2017
An old dichotomy in the space(r) age
Khamis R and Mylotte D
free

EXPERT REVIEW

10.4244/EIJ-D-17-00505 Sep 24, 2017
Mitral valve: repair/clips/cinching/chordae
Vahanian A et al
free

10.4244/EIJV16I17A252 Apr 20, 2021
How to eliminate mitral regurgitation definitively: the eternal dilemma?
Modine T and Ben Ali W
free
Trending articles
339.08

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
314.58

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
295.45

Expert consensus

10.4244/EIJ-D-21-00898 Sep 20, 2022
Intravascular ultrasound guidance for lower extremity arterial and venous interventions
Secemsky E et al
free
74.35

Clinical research

10.4244/EIJ-D-22-01062 Aug 21, 2023
Impact of mitral regurgitation aetiology on the outcomes of transcatheter aortic valve implantation
Doldi PM et al
54.75

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
42.95

Clinical research

10.4244/EIJ-D-23-00282 Jul 17, 2023
Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR
Kodali SK et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved